Clinical Trial

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Protocol Amendment History 3 changes
notable Enrollment reduced: 596 -> 500 participants 2026-05-28
notable Primary completion pushed: 2028-09-15 -> 2028-12-15 2026-05-28
minor Completion moved earlier: 2031-05-15 -> 2030-11-15 2026-05-28
Trial Details
NCT Number NCT07100080
Lead Sponsor Bristol-Myers Squibb
Conditions Non-Small Cell Lung Cancer
Enrollment 500 participants
Start Date 2025-11-05
Primary Completion 2028-12-15 (estimated)
Study Completion 2030-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-29